A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of TT223 in Patients With Type 2 Diabetes Treated With Metformin and/or TZD
Phase of Trial: Phase II
Latest Information Update: 20 Jun 2013
At a glance
- Drugs TT 223 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2010 Results presented in a Transition Therapeutics media release.